Razer Moro schreef op 26 juli 2016 10:47:
Galapagos NV (GLPG) Position Raised by Deerfield Management Co.
Posted by Stuart Ham on Jul 25th, 2016 // No Comments
Galapagos NV logoDeerfield Management Co. boosted its stake in shares of Galapagos NV (NASDAQ:GLPG) by 79.0% during the first quarter, Holdings Channel reports. The institutional investor owned 327,626 shares of the company’s stock after buying an additional 144,626 shares during the period. Deerfield Management Co. owned approximately 0.71% of Galapagos NV worth $13,701,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. EverPoint Asset Management LLC purchased a new position in shares of Galapagos NV during the fourth quarter valued at approximately $3,143,000. GLG Partners LP boosted its position in shares of Galapagos NV by 501.8% in the fourth quarter. GLG Partners LP now owns 70,309 shares of the company’s stock valued at $4,421,000 after buying an additional 58,625 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Galapagos NV by 46.4% in the fourth quarter. Macquarie Group Ltd. now owns 34,533 shares of the company’s stock valued at $2,171,000 after buying an additional 10,952 shares in the last quarter. Landscape Capital Management L.L.C. boosted its position in shares of Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock valued at $727,000 after buying an additional 9,288 shares in the last quarter. Finally, Clough Capital Partners L P purchased a new position in shares of Galapagos NV during the fourth quarter valued at approximately $7,910,000.
Galapagos NV (NASDAQ:GLPG) traded down 0.36% during trading on Monday, reaching $52.71. 28,214 shares of the company’s stock were exchanged. Galapagos NV has a 12-month low of $37.03 and a 12-month high of $65.70. The company’s market cap is $2.42 billion. The stock’s 50-day moving average is $54.25 and its 200-day moving average is $48.91.
Several equities analysts recently commented on GLPG shares. Zacks Investment Research cut shares of Galapagos NV from a “buy” rating to a “hold” rating in a research note on Monday, July 4th. Credit Suisse Group AG reaffirmed a “hold” rating and set a $48.00 price objective on shares of Galapagos NV in a research note on Friday, June 17th. Morgan Stanley cut their price target on shares of Galapagos NV from $92.00 to $89.00 and set an “overweight” rating for the company in a research note on Monday, May 2nd. Finally, Cowen and Company reissued a “buy” rating on shares of Galapagos NV in a research note on Saturday, April 30th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of €65.50 ($72.78).
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.